Aadi bioscience announces exploratory biomarker data from patients in its ampect trial and expanded access program to be presented at 2022 asco annual meeting

Target tumor reductions observed in advanced malignant pecoma patients harboring tsc1 or tsc2 inactivating alterations regardless of prior mtor inhibitor exposure target tumor reductions observed in advanced malignant pecoma patients harboring tsc1 or tsc2 inactivating alterations regardless of prior mtor inhibitor exposure
AADI Ratings Summary
AADI Quant Ranking